NASDAQ: TXMDTherapeuticsmd Inc Stock
$1.73-0.05 (-2.81%)
Updated Sep 6, 2024
TXMD Price
$1.73
Fair Value Price
N/A
Market Cap
$19.95M
52 Week Low
$1.43
52 Week High
$3.73
P/E
-3.26x
P/B
0.72x
P/S
18.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$996.00k
Earnings
-$6.09M
Gross Margin
100%
Operating Margin
-624.3%
Profit Margin
-610.9%
Debt to Equity
0.45
Operating Cash Flow
-$9M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TXMD Overview
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TXMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TXMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TXMD is good value based on its book value relative to its share price (0.72x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.28x)
P/B vs Industry Valuation
TXMD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TXMD due diligence checks available for Premium users.
Be the first to know about important TXMD news, forecast changes, insider trades & much more!
TXMD News
Valuation
TXMD fair value
Fair Value of TXMD stock based on Discounted Cash Flow (DCF)
Price
$1.73
Fair Value
-$1.80
Undervalued by
196.02%
TXMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TXMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.26x
Industry
20.61x
Market
24.57x
TXMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.72x
Industry
2.28x
TXMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TXMD's financial health
Profit margin
Revenue
$234.0k
Net Income
-$1.1M
Profit Margin
-465.8%
TXMD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TXMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$40.1M
Liabilities
$12.5M
Debt to equity
0.45
TXMD's short-term assets ($11.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TXMD's short-term assets ($11.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TXMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TXMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$665.0k
Investing
$0.0
Financing
$0.0
TXMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TXMD vs Pharmaceutical Stocks
Therapeuticsmd Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.